Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma

医学 来那度胺 内科学 耐火材料(行星科学) 多发性骨髓瘤 护理标准 肿瘤科 生物 天体生物学
作者
Jesús F. San Miguel,Binod Dhakal,Kwee Yong,Andrew G Spencer,Sébastien Anguille,María‐Victoria Mateos,Carlos Fernández de Larrea,Joaquín Martínez‐López,Philippe Moreau,Cyrille Touzeau,Xavier P Leleu,Irit Mazza Avivi,Michèle Cavo,Tadao Ishida,Seok Jin Kim,Wilfried W. H. Roeloffzen,Niels W.C.J. van de Donk,Dominik Dytfeld,Surbhi Sidana,Luciano J. Costa
出处
期刊:The New England Journal of Medicine [Massachusetts Medical Society]
卷期号:389 (4): 335-347 被引量:939
标识
DOI:10.1056/nejmoa2303379
摘要

BACKGROUND: Ciltacabtagene autoleucel (cilta-cel), a B-cell maturation antigen (BCMA)-directed CAR T-cell therapy, is effective in heavily pretreated patients with relapsed or refractory multiple myeloma. We investigated cilta-cel in earlier treatment lines in patients with lenalidomide-refractory disease. METHODS: In this phase 3, randomized, open-label trial, we assigned patients with lenalidomide-refractory multiple myeloma to receive cilta-cel or the physician's choice of effective standard care. All the patients had received one to three previous lines of treatment. The primary outcome was progression-free survival. RESULTS: A total of 419 patients underwent randomization (208 to receive cilta-cel and 211 to receive standard care). At a median follow-up of 15.9 months (range, 0.1 to 27.3), the median progression-free survival was not reached in the cilta-cel group and was 11.8 months in the standard-care group (hazard ratio, 0.26; 95% confidence interval [CI], 0.18 to 0.38; P<0.001). Progression-free survival at 12 months was 75.9% (95% CI, 69.4 to 81.1) in the cilta-cel group and 48.6% (95% CI, 41.5 to 55.3) in the standard-care group. More patients in the cilta-cel group than in the standard-care group had an overall response (84.6% vs. 67.3%), a complete response or better (73.1% vs. 21.8%), and an absence of minimal residual disease (60.6% vs. 15.6%). Death from any cause was reported in 39 patients and 46 patients, respectively (hazard ratio, 0.78; 95% CI, 0.5 to 1.2). Most patients reported grade 3 or 4 adverse events during treatment. Among the 176 patients who received cilta-cel in the as-treated population, 134 (76.1%) had cytokine release syndrome (grade 3 or 4, 1.1%; no grade 5), 8 (4.5%) had immune effector cell-associated neurotoxicity syndrome (all grade 1 or 2), 1 had movement and neurocognitive symptoms (grade 1), 16 (9.1%) had cranial nerve palsy (grade 2, 8.0%; grade 3, 1.1%), and 5 (2.8%) had CAR-T-related peripheral neuropathy (grade 1 or 2, 2.3%; grade 3, 0.6%). CONCLUSIONS: A single cilta-cel infusion resulted in a lower risk of disease progression or death than standard care in lenalidomide-refractory patients with multiple myeloma who had received one to three previous therapies. (Funded by Janssen and Legend Biotech; CARTITUDE-4 ClinicalTrials.gov number, NCT04181827.).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
爱听歌秋尽完成签到,获得积分10
刚刚
刚刚
Eli发布了新的文献求助10
1秒前
1秒前
可爱的函函的应助被Serendipity采纳,获得10
1秒前
tutu发布了新的文献求助10
2秒前
ddt完成签到,获得积分10
2秒前
3秒前
无条件完成签到,获得积分10
3秒前
asd2221发布了新的文献求助10
3秒前
糖醋排骨完成签到,获得积分10
4秒前
4秒前
ocean完成签到,获得积分10
4秒前
6秒前
RAN18完成签到,获得积分10
6秒前
清爽的莆完成签到 ,获得积分10
6秒前
豆豆豆豆完成签到,获得积分10
7秒前
daomaihu发布了新的文献求助100
7秒前
荼蘼发布了新的文献求助10
7秒前
4645发布了新的文献求助10
7秒前
8秒前
Maestro_S的应助被zone采纳,获得10
8秒前
廖玲丽完成签到 ,获得积分10
9秒前
9秒前
10秒前
tang发布了新的文献求助10
10秒前
10秒前
milion完成签到,获得积分10
10秒前
star完成签到,获得积分10
10秒前
12秒前
易怀亮完成签到,获得积分10
12秒前
Luxi发布了新的文献求助10
12秒前
12秒前
12秒前
Z_Z完成签到,获得积分0
12秒前
cs完成签到,获得积分10
13秒前
tutu发布了新的文献求助10
13秒前
万物更始完成签到,获得积分10
13秒前
在水一方的应助被Eli采纳,获得10
14秒前
Ning完成签到,获得积分10
14秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
Resource Recovery Handbook 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8175157
求助须知:如何正确求助?哪些是违规求助? 9566975
关于积分的说明 21789458
捐赠科研通 7769647
什么是DOI,文献DOI怎么找? 3431836
关于科研通互助平台的介绍 2556078
邀请新用户注册赠送积分活动 2477241